Novavax applies for a license to use the COVID-19 vaccine as a booster shot in the US

Novavax filed an application with the US Food and Drug Administration amid the slow rollout of the COVID-19 vaccine in the US. Novavax’s COVID-19 vaccine was approved in the US in July, with the hope that it will convince vaccine skeptics to get vaccinated.

“It is important that people are given a choice as they assess how to maintain protection against COVID-19,” Chief Executive Stanley Erck said in a statement, referring to the company’s COVID-19 vaccine. Novavax uses traditional technology.

Accordingly, this is a protein-based vaccine that uses purified viral fragments to promote an immune response, a technology that has been used to make vaccines against many diseases including hepatitis B and C. flu.

Novavax applies for a license to use the COVID-19 vaccine as a booster shot in the US - Photo 1.

To date, more than 9,700 doses of Novavax vaccine have been administered in the United States out of a total of 606 million doses administered overall. More than 67% of the US population has received two basic doses of the COVID-19 vaccine, according to the latest US federal data.

Last week, Novavax halved its full-year revenue forecast as it expected no significant sales of its COVID-19 vaccine product this year in the US due to oversupply. excess and weak demand.

footerFbSdk.init(); });

Leave a Comment